Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

BACKGROUND: The identification of molecular and genetic markers to predict or monitor the efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal cancer (mCRC). METHODS: Plasma levels of vascular endothelial growth factor (VEGF), placental growth factor (PlGF),...

Descripción completa

Detalles Bibliográficos
Autores principales: Loupakis, F, Cremolini, C, Fioravanti, A, Orlandi, P, Salvatore, L, Masi, G, Di Desidero, T, Canu, B, Schirripa, M, Frumento, P, Di Paolo, A, Danesi, R, Falcone, A, Bocci, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078596/
https://www.ncbi.nlm.nih.gov/pubmed/21407216
http://dx.doi.org/10.1038/bjc.2011.85

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078596/
https://www.ncbi.nlm.nih.gov/pubmed/21407216
http://dx.doi.org/10.1038/bjc.2011.85

Ejemplares similares